enGene
enGene is a biotechnology company focused on developing non-viral gene therapies for underserved diseases, utilizing its novel Dually Derivatized Oligochitosan (DDX) platform for targeted delivery to mucosal tissues.
Company Overview
enGene is engaged in developing locally administered, non-viral gene therapies aimed at addressing underserved diseases. The company employs a novel gene delivery platform that enables localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Gene Delivery Platform
At the core of enGene's innovation is the Dually Derivatized Oligochitosan (DDX) platform. This platform plays a critical role in streamlining the use of genetic medicines by allowing efficient and precise delivery of therapeutic genes. By transforming mucosal cells into factories that produce proteins and RNAs, enGene's technology aims to significantly impact the treatment of various conditions.
Focus on Mucosal Gene Therapies
enGene develops medicines designed to transform mucosal cells into therapeutic production factories. These cells produce essential proteins and RNAs, offering new treatment possibilities for diseases that are underserved by current therapies. The focus on mucosal tissues enables localized treatment with potentially fewer systemic side effects.
EG-70 Non-viral Gene Therapy
One of enGene's key developments is EG-70, a non-viral gene therapy currently in development for the treatment of non-muscle invasive bladder cancer (NMIBC). This therapy exemplifies the company's approach to addressing serious diseases with innovative, locally administered genetic treatments.